122 related articles for article (PubMed ID: 1822001)
1. The uptake and efflux of doxorubicin by a sensitive human bladder cancer cell line and its doxorubicin-resistant subline.
Usansky JI; Liebert M; Wedemeyer G; Grossman HB; Wagner JG
Sel Cancer Ther; 1991; 7(4):139-50. PubMed ID: 1822001
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of multiple drug resistance in human bladder cancer cell lines.
Shinohara N; Liebert M; Wedemeyer G; Chang JH; Grossman HB
J Urol; 1993 Aug; 150(2 Pt 1):505-9. PubMed ID: 8100862
[TBL] [Abstract][Full Text] [Related]
3. Effect of verapamil on the uptake and efflux of etoposide (VP16) in both sensitive and resistant cancer cells.
Feng MR; Liebert M; Wedemeyer G; Grossman HB; Mancini WR; Williams M; Wagner JG
Sel Cancer Ther; 1991; 7(2):75-83. PubMed ID: 1754730
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines.
Slovak ML; Hoeltge GA; Dalton WS; Trent JM
Cancer Res; 1988 May; 48(10):2793-7. PubMed ID: 2896069
[TBL] [Abstract][Full Text] [Related]
5. Effect of S9788, cyclosporin A and verapamil on intracellular distribution of THP-doxorubicin in multidrug-resistant K562 tumor cells, as studied by laser confocal microspectrofluorometry.
Sebille S; Morjani H; Poullain MG; Manfait M
Anticancer Res; 1994; 14(6A):2389-93. PubMed ID: 7825978
[TBL] [Abstract][Full Text] [Related]
6. Relationship between expression of P-glycoprotein and efficacy of trifluoperazine in multidrug-resistant cells.
Ganapathi R; Kuo T; Teeter L; Grabowski D; Ford J
Mol Pharmacol; 1991 Jan; 39(1):1-8. PubMed ID: 1670962
[TBL] [Abstract][Full Text] [Related]
7. Modulation in vitro and in vivo of cytotoxicity but not cellular levels of doxorubicin by the calmodulin inhibitor trifluoperazine is dependent on the level of resistance.
Ganapathi R; Schmidt H; Grabowski D; Melia M; Ratliff N
Br J Cancer; 1988 Sep; 58(3):335-40. PubMed ID: 3179186
[TBL] [Abstract][Full Text] [Related]
8. MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells.
Tanaka M; Koul D; Davies MA; Liebert M; Steck PA; Grossman HB
Oncogene; 2000 Nov; 19(47):5406-12. PubMed ID: 11103942
[TBL] [Abstract][Full Text] [Related]
9. Bcl-2 and mdr-1 gene expression during doxorubicin-induced apoptosis in murine leukemic P388 and P388/R84 cells.
Ramachandran C; You W; Krishan A
Anticancer Res; 1997; 17(5A):3369-76. PubMed ID: 9413174
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of adriamycin-induced cytotoxicity by increasing retention and inhibition of DNA repair in DOX-resistant P388 cell lines with new calcium channel blocker, DMDP.
Bankusli I; Yin MB; Mazzoni A; Abdellah AJ; Rustum YM
Anticancer Res; 1989; 9(3):567-74. PubMed ID: 2764503
[TBL] [Abstract][Full Text] [Related]
11. Differential effect of the calmodulin inhibitor trifluoperazine in modulating cellular accumulation, retention and cytotoxicity of doxorubicin in progressively doxorubicin-resistant L1210 mouse leukemia cells. Lack of correlation between cellular doxorubicin levels and expression of resistance.
Ganapathi R; Grabowski D
Biochem Pharmacol; 1988 Jan; 37(2):185-93. PubMed ID: 3342075
[TBL] [Abstract][Full Text] [Related]
12. Effects of amiodarone, cyclosporin A, and PSC 833 on the cytotoxicity of mitoxantrone, doxorubicin, and vincristine in non-P-glycoprotein human small cell lung cancer cell lines.
van der Graaf WT; de Vries EG; Timmer-Bosscha H; Meersma GJ; Mesander G; Vellenga E; Mulder NH
Cancer Res; 1994 Oct; 54(20):5368-73. PubMed ID: 7923167
[TBL] [Abstract][Full Text] [Related]
13. Increase in doxorubicin cytotoxicity by carvedilol inhibition of P-glycoprotein activity.
Jonsson O; Behnam-Motlagh P; Persson M; Henriksson R; Grankvist K
Biochem Pharmacol; 1999 Dec; 58(11):1801-6. PubMed ID: 10571255
[TBL] [Abstract][Full Text] [Related]
14. Establishment and characterization of doxorubicin-resistant human bladder cancer cell line, KK47/ADM.
Kimiya K; Naito S; Soejima T; Sakamoto N; Kotoh S; Kumazawa J; Tsuruo T
J Urol; 1992 Aug; 148(2 Pt 1):441-5. PubMed ID: 1353119
[TBL] [Abstract][Full Text] [Related]
15. Reduction of doxorubicin resistance in P-glycoprotein overexpressing cells by hybrid cell-penetrating and drug-binding peptide.
Zheng Z; Aojula H; Clarke D
J Drug Target; 2010 Jul; 18(6):477-87. PubMed ID: 20088680
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Pgp activity and cell cycle-dependent chemosensitivity to doxorubicin in the multidrug-resistant LoVo human colon cancer cell line.
Toffoli G; Corona G; Gigante M; Boiocchi M
Eur J Cancer; 1996 Aug; 32A(9):1591-7. PubMed ID: 8911123
[TBL] [Abstract][Full Text] [Related]
17. Partial circumvention of P-glycoprotein-mediated multidrug resistance by doxorubicin-14-O-hemiadipate.
Leontieva OV; Preobrazhenskaya MN; Bernacki RJ
Invest New Drugs; 2002 Feb; 20(1):35-48. PubMed ID: 12003193
[TBL] [Abstract][Full Text] [Related]
18. Direct relation of DNA lesions in multidrug-resistant human myeloma cells to intracellular doxorubicin concentration.
Bellamy WT; Dorr RT; Dalton WS; Alberts DS
Cancer Res; 1988 Nov; 48(22):6360-4. PubMed ID: 3180055
[TBL] [Abstract][Full Text] [Related]
19. Reversal of p-glycoprotein-mediated multidrug resistance by CJX1, an amlodipine derivative, in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
Ji BS; He L; Liu GQ
Life Sci; 2005 Sep; 77(18):2221-32. PubMed ID: 15967469
[TBL] [Abstract][Full Text] [Related]
20. Structure-dependent antitumor activities of novel anthracyclines YM1, YM3, YM4 and YM6: drug transport properties and effects on biomacromolecule synthesis in drug sensitive and resistant leukemia cells.
Jiang XR; Macey MG; Kelsey SM; Collins PW; Gutteridge CN; Miki T; Adachi K; Yamabe S; Newland AC
J Chemother; 1993 Oct; 5(5):334-43. PubMed ID: 7508975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]